Autopsy report · NCT00550862
Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)
Cause of deathFunding or business, also staffing, sites or logistics
“Study stopped by sponsor due to administrative reasons”
Life of this trial
- Ran for about 3 years 2 months before it stopped.
- 165 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Intercept Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Liver Cirrhosis, Biliary
- Interventions
- INT-747; Ursodeoxycholic Acid (URSO); Placebo
- Participants
- 165
- Sites
- 32
- Countries
- Austria, Canada, France, Germany, Netherlands, Spain, United Kingdom, United States
Trials that died the same way
- Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302
“Study was stopped by the Sponsor” - A Natural History Study of Patients With G2019S LRRK2 Parkinson's Disease
“Sponsor stopped the study” - Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury
“Study has been stopped by sponsor decision.” - Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer
“Study Terminated by Sponsor” - Comprehensive Medication Monitoring on Heart Failure Patient Outcomes
“Study terminated by sponsor for commercial reasons”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.